HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

[1]  S. Lin-Shiau,et al.  Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. , 2008, Pharmacology & toxicology.

[2]  M. Minden,et al.  Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. , 2001, Blood.

[3]  C. Elson,et al.  Sterol‐independent regulation of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase in tumor cells , 2001, Molecular carcinogenesis.

[4]  Inkyoung Lee,et al.  Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. , 2001, Carcinogenesis.

[5]  M. Minden,et al.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.

[6]  W. Weber.  Drug firm withdraws statin from the market , 2001, The Lancet.

[7]  D. Nowis,et al.  In vitro antitumor activity of cerivastatin, a novel and potent HMG‐CoA reductase inhibitor , 2001, FEBS letters.

[8]  J. Soria,et al.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.

[9]  A. Gotto,et al.  Pleiotropic effects of statins: do they matter? , 2001, Current opinion in lipidology.

[10]  F. Mach,et al.  Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[12]  M. Salmona,et al.  In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. Hohl,et al.  Interaction of cytosine arabinoside and lovastatin in human leukemia cells. , 2001, Leukemia research.

[14]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[15]  F. Luft,et al.  Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor , 2001, Circulation.

[16]  M. Minden,et al.  Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Stein,et al.  HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. , 2001, Carcinogenesis.

[18]  M. Lishner,et al.  Effect of Simvastatin Alone and in Combination With Cytosine Arabinoside on the Proliferation of Myeloid Leukemia Cell Lines , 2001, Journal of Investigative Medicine.

[19]  M. Hanefeld.  CLINICAL RATIONALE FOR ROSUVASTATIN, A POTENT NEW HMG‐COA REDUCTASE INHIBITOR , 2001, International journal of clinical practice.

[20]  M. Tatsuta,et al.  Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. , 2001, Cancer research.

[21]  E. Wang,et al.  HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.

[22]  S. Wright,et al.  Statins suppress THP‐1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation , 2001, Journal of leukocyte biology.

[23]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[24]  Hua Tang,et al.  3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Block Calcium-dependent Tyrosine Kinase Pyk2 Activation by Angiotensin II in Vascular Endothelial Cells , 2001, The Journal of Biological Chemistry.

[25]  L. Penn.  Apoptosis modulators as cancer therapeutics. , 2001, Current opinion in investigational drugs.

[26]  Y. Matsuzawa,et al.  Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .

[27]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[28]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[29]  T. Pedersen.  Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. , 2001, The American journal of cardiology.

[30]  J. Dichgans,et al.  Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells , 2001, Acta Neuropathologica.

[31]  M. Minden,et al.  Lovastatin Induced Control of Blast Cell Growth in an Elderly Patient with Acute Myeloblastic Leukemia , 2001, Leukemia & lymphoma.

[32]  Yung-Hyun Choi,et al.  Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint , 2000, Oncogene.

[33]  D. Gómez-Coronado,et al.  Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. , 2000, Atherosclerosis.

[34]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[35]  H. Mabuchi,et al.  NK-104: a novel synthetic HMG-CoA reductase inhibitor , 2000, Expert opinion on investigational drugs.

[36]  R. Naoumova,et al.  Novel lipid-regulating drugs , 2000, Expert opinion on investigational drugs.

[37]  G. Gores,et al.  Apoptosis in cancer: cause and cure , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[39]  S. Ōmura,et al.  Lovastatin and simvastatin are modulators of the proteasome. , 2000, The international journal of biochemistry & cell biology.

[40]  L. Blais,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.

[41]  P. Hansten,et al.  Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. , 2000, Archives of internal medicine.

[42]  L. Pan,et al.  Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin , 2000, Leukemia.

[43]  W. Mück.  Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.

[44]  D. Vordermark,et al.  Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. , 2000, Anticancer research.

[45]  T. Mjörndal,et al.  HMG-CoA Reductase Inhibitors and Myotoxicity , 2000, Drug safety.

[46]  T. Stokłosa,et al.  Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[48]  M. Sinensky,et al.  Recent advances in the study of prenylated proteins. , 2000, Biochimica et biophysica acta.

[49]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. , 2000, Current opinion in cell biology.

[50]  W. Insull,et al.  Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolaemia: The Pivotal Placebo-Controlled Clinical Trial , 2000 .

[51]  M. Jakóbisiak,et al.  Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  J. Deisenhofer,et al.  Crystal structure of the catalytic portion of human HMG‐CoA reductase: insights into regulation of activity and catalysis , 2000, The EMBO journal.

[53]  B. H. Stewart,et al.  Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter , 2000, Pharmaceutical Research.

[54]  Jen-kun Lin,et al.  Induction of Apoptosis by Lovastatin through Activation of Caspase‐3 and DNase II in Leukaemia HL‐60 Cells , 2000 .

[55]  M. Minden,et al.  Lovastatin Induces a Pronounced Differentiation Response in Acute Myeloid Leukemias , 2000, Leukemia & lymphoma.

[56]  Wei Wang,et al.  Mevalonate Prevents Lovastatin-Induced Apoptosis in Medulloblastoma Cell Lines , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[57]  R. Gardner,et al.  A Highly Conserved Signal Controls Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) Reductase in Eukaryotes* , 1999, The Journal of Biological Chemistry.

[58]  M. Gorospe,et al.  Activation of the cholesterol pathway and Ras maturation in response to stress , 1999, Oncogene.

[59]  S. Polak‐Charcon,et al.  Impaired Regulation of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Degradation in Lovastatin-resistant Cells* , 1999, The Journal of Biological Chemistry.

[60]  C. Rao,et al.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.

[61]  H. Mo,et al.  Isoprenoid-Mediated Inhibition of Mevalonate Synthesis: Potential Application to Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[62]  M. Moghadasian.  Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1999, Life sciences.

[63]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[64]  B. Foster,et al.  Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line , 1999, Oncogene.

[65]  K. Keyomarsi,et al.  Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Y. Y. Lee,et al.  Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. , 1999, Anticancer research.

[67]  A. Dabrowska,et al.  Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis , 1999, International journal of cancer.

[68]  M. Hanefeld,et al.  Efficacy and Safety of 300 μg and 400 μg Cerivastatin Once Daily in Patients with Primary Hypercholesterolemia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study , 1999, The Journal of international medical research.

[69]  S. Jung,et al.  Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[70]  L. Kindred,et al.  Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. , 1999, The American journal of cardiology.

[71]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[72]  H. Yeger,et al.  Lovastatin-induced Apoptosis of Human Medulloblastoma Cell Lines in vitro , 1999, Journal of Neuro-Oncology.

[73]  M. Minden,et al.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.

[74]  R. Bonfil,et al.  Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma , 1999, Clinical & Experimental Metastasis.

[75]  S. Lowe,et al.  Apoptosis and therapy , 1999, The Journal of pathology.

[76]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[77]  E. Laws,et al.  A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. , 1998, American journal of clinical oncology.

[78]  Martin Raff,et al.  Cell suicide for beginners , 1998, Nature.

[79]  K. Keyomarsi,et al.  Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 , 1998, Oncogene.

[80]  J. M. Malinowski.  Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[81]  A. Ortiz,et al.  3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. , 1998, Circulation research.

[82]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[83]  M. Farnier,et al.  Current and future treatment of hyperlipidemia: the role of statins. , 1998, The American journal of cardiology.

[84]  D. Gomez,et al.  Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis , 1998, Breast Cancer Research and Treatment.

[85]  D. Catovsky,et al.  Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice , 1998, British journal of haematology.

[86]  A. Vasudevan,et al.  Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[87]  R. Kratzke,et al.  Lovastatin induces apoptosis in malignant mesothelioma cells. , 1998, American journal of respiratory and critical care medicine.

[88]  C. Townsend,et al.  Insulin‐like growth factor‐I promotes multidrug resistance in MCLM colon cancer cells , 1998, Journal of cellular physiology.

[89]  Xiao-Fan Wang,et al.  Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[90]  R. Muschel,et al.  Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. , 1998, Cancer research.

[91]  H. Kalthoff,et al.  Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. , 1998, International journal of oncology.

[92]  A. Faggiotto,et al.  Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. , 1997, Atherosclerosis.

[93]  Y. Nagata,et al.  In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells , 1997, Journal of Neuro-Oncology.

[94]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[95]  R. V. van Leeuwen,et al.  Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. , 1997, Biochimica et biophysica acta.

[96]  K. Keyomarsi,et al.  Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. , 1997, Cancer research.

[97]  D. McTavish,et al.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. , 1997, Drugs.

[98]  G. Stoner,et al.  Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. , 1996, Cancer letters.

[99]  T. Narisawa,et al.  Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. , 1996, The Tohoku journal of experimental medicine.

[100]  J. Wyche,et al.  Lovastatin induces apoptosis in a metastatic ovarian tumour cell line. , 1996, Cell death and differentiation.

[101]  L. Altucci,et al.  Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. , 1996, Biochemical and biophysical research communications.

[102]  H. Yeger,et al.  HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.

[103]  G. Plosker,et al.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. , 1996, Drugs.

[104]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  O. Larsson,et al.  Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. , 1996, Experimental cell research.

[106]  L. Altucci,et al.  17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. , 1996, Oncogene.

[107]  D. Samid,et al.  Lipid Metabolism as a Target for Brain Cancer Therapy: Synergistic Activity of Lovastatin and Sodium Phenylacetate Against Human Glioma Cells , 1996, Journal of neurochemistry.

[108]  G. Plosker,et al.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. , 1995, Drugs.

[109]  D. Catovsky,et al.  The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[110]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[111]  R. Law,et al.  Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. , 1994, Biochemical and biophysical research communications.

[112]  G. Juliusson,et al.  Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy- 3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells , 1994 .

[113]  R. Larsson,et al.  Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. , 1994, Anti-cancer drugs.

[114]  A. Umezawa,et al.  Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. , 1994, Carcinogenesis.

[115]  L. Hengst,et al.  A cell cycle-regulated inhibitor of cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[116]  F. Mollinedo,et al.  Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. , 1994, Biochemical and biophysical research communications.

[117]  R. Clutterbuck,et al.  Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. , 1994, Leukemia.

[118]  G. Favre,et al.  Importance of mevalonate‐derived products in the control of HMG‐CoA reductase activity and growth of human lung adenocarcinoma cell line a549 , 1993, International journal of cancer.

[119]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[120]  V. F. Mauro.  Clinical Pharmacokinetics and Practical Applications of Simvastatin , 1993, Clinical pharmacokinetics.

[121]  D. Samid,et al.  Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation , 1993, International journal of cancer.

[122]  Y. Matsuzawa,et al.  Effect of Pravastatin, a Potent 3‐Hydroxy‐3‐methylgliitaryl‐coenzyme A Reductase Inhibitor, on Survival of AH130 Hepatoma‐bearing Rats , 1992, Japanese journal of cancer research : Gann.

[123]  K. Bischoff,et al.  Biosynthesis and characterization of (S)-and (R)-3-hydroxy-3-methylglutaryl coenzyme A. , 1992, Biochemical medicine and metabolic biology.

[124]  S. Sumi,et al.  Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. , 1992, Gastroenterology.

[125]  G. Butti,et al.  Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. , 1992, Cancer research.

[126]  H. Buchwald.  Cholesterol inhibition, cancer, and chemotherapy , 1992, The Lancet.

[127]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[128]  D. Russell.  Cholesterol biosynthesis and metabolism , 1992, Cardiovascular Drugs and Therapy.

[129]  P. Stacpoole,et al.  In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. , 1991, Journal of lipid research.

[130]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[131]  S. Sebti,et al.  Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. , 1991, Cancer communications.

[132]  Z. Darżynkiewicz,et al.  Cell cycle-specific effects of lovastatin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[133]  D. Lowy,et al.  Inhibition of cell growth by lovastatin is independent of ras function. , 1991, Cancer research.

[134]  Y. Matsuzawa,et al.  Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. , 1990, Cancer research.

[135]  B. Kabakoff,et al.  Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. , 1990, Archives of biochemistry and biophysics.

[136]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[137]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[138]  R. Defendini,et al.  Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1985, Journal of Clinical Investigation.

[139]  M. Brown,et al.  Amplification of the gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not for the 53-kDa protein, in UT-1 cells. , 1983, The Journal of biological chemistry.

[140]  E Niskanen,et al.  MARROW TRANSPLANTATION , 1977, Duodecim; laaketieteellinen aikakauskirja.

[141]  B. Tang,et al.  Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver , 2004, European Journal of Clinical Pharmacology.

[142]  Keunchil Park,et al.  Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma , 2004, Investigational New Drugs.

[143]  P. M. Davis,et al.  Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. , 2001, International immunopharmacology.

[144]  S. C. Armstrong,et al.  Concise guide to the cytochrome P450 system : drug interaction principles for medical practice , 2001 .

[145]  L. Penn,et al.  Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  W. Insull,et al.  Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. , 2000, The Journal of international medical research.

[147]  J. Farmer,et al.  Comparative Tolerability of the HMG-CoA Reductase Inhibitors , 2000, Drug safety.

[148]  S H Kaufmann,et al.  Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.

[149]  M. Lutter,et al.  Biochemical pathways of caspase activation during apoptosis. , 1999, Annual review of cell and developmental biology.

[150]  M. Santillo,et al.  Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. , 1999, Anticancer research.

[151]  O. Scharovsky,et al.  Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. , 1998, Cancer biotherapy & radiopharmaceuticals.

[152]  M. Marcelli,et al.  Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.

[153]  D. Seidel,et al.  [HMG-CoA reductase inhibitors]. , 1998, Der Internist.

[154]  J. Chovancová,et al.  Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin. , 1997, Neoplasma.

[155]  D. Catovsky,et al.  A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. , 1997, Leukemia & lymphoma.

[156]  O. Larsson.  HMG-CoA reductase inhibitors: role in normal and malignant cells. , 1996, Critical reviews in oncology/hematology.

[157]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[158]  J. Gołąb,et al.  Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice. , 1995, Neoplasma.

[159]  R. Clutterbuck,et al.  Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. , 1994, Leukemia.

[160]  G. Juliusson,et al.  Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. , 1994, Blood.

[161]  Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. , 1993, Archives of internal medicine.

[162]  S. Specht,et al.  Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. , 1993, Invasion & metastasis.

[163]  R. Olson,et al.  Biosynthesis of ubiquinone. , 1983, Vitamins and hormones.